Free Trial

Regeneron Pharmaceuticals, Inc. $REGN Stock: Aberdeen Group plc Increases Holdings

Regeneron Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Aberdeen Group increased its Regeneron stake by 560.7% in the third quarter, adding 569,476 shares to own 671,042 shares worth about $508.8 million. Institutional investors collectively hold 83.31% of the company.
  • Regeneron reported quarterly EPS of $20.07, beating estimates of $16.51, while revenue rose 36.3% year over year to $5.12 billion.
  • Analysts have a consensus “Moderate Buy” rating and an average price target of $898.97; recent target increases included Goldman Sachs at $972 and TD Cowen at $980.
  • Interested in Regeneron Pharmaceuticals? Here are five stocks we like better.

Aberdeen Group plc raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 560.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 671,042 shares of the biopharmaceutical company's stock after buying an additional 569,476 shares during the quarter. Aberdeen Group plc owned about 0.65% of Regeneron Pharmaceuticals worth $508,831,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $5,682,636,000. State Street Corp boosted its holdings in Regeneron Pharmaceuticals by 3.6% during the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company's stock worth $3,014,621,000 after purchasing an additional 170,210 shares during the last quarter. Bank of America Corp DE grew its stake in Regeneron Pharmaceuticals by 8.5% in the second quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company's stock valued at $805,023,000 after purchasing an additional 101,469 shares in the last quarter. Amundi grew its stake in Regeneron Pharmaceuticals by 0.4% in the second quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company's stock valued at $631,983,000 after purchasing an additional 3,742 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $473,872,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on REGN shares. The Goldman Sachs Group lifted their price target on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Royal Bank Of Canada upped their price objective on Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the company a "sector perform" rating in a research note on Monday, November 2nd. Robert W. Baird raised their price target on Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the company a "neutral" rating in a report on Monday, November 2nd. Sanford C. Bernstein upped their price objective on shares of Regeneron Pharmaceuticals from $756.00 to $812.00 and gave the company a "market perform" rating in a report on Monday, November 2nd. Finally, TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a "buy" rating in a research note on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $898.97.

Check Out Our Latest Stock Report on REGN

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $955.47 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $991.73. The stock's 50 day moving average is $816.17 and its 200-day moving average is $747.36. The firm has a market capitalization of $98.84 billion, a price-to-earnings ratio of 19.92, a PEG ratio of 1.26 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts' consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. During the same period last year, the firm earned $11.83 earnings per share. The business's quarterly revenue was up 36.3% compared to the same quarter last year. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.30%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 4,466 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the sale, the executive vice president owned 38,906 shares in the company, valued at $37,563,353.94. This represents a 10.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Andrew J. Murphy sold 4,147 shares of the company's stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the sale, the insider owned 47,833 shares in the company, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 27,028 shares of company stock worth $25,025,950. Company insiders own 6.97% of the company's stock.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company's medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Recommended Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?

Before you consider Regeneron Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.

While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines